Victoria Feidt
Family · Millersburg, PANPI 1093256695
Payments from drug & device makers
Across 207 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$632
- Lilly USA, LLC$631
- Novo Nordisk$620
- AstraZeneca$331
- Boehringer Ingelheim$203
- Pfizer$143
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,592100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $632 |
| Lilly USA, LLC | 45 | $631 |
| Novo Nordisk | 37 | $620 |
| AstraZeneca | 14 | $331 |
| Boehringer Ingelheim | 12 | $203 |
| Pfizer | 8 | $143 |
| Teva Pharmaceuticals USA, Inc. | 6 | $125 |
| Cequr Corporation | 3 | $101 |
| Otsuka America Pharmaceutical, Inc. | 5 | $97 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $86 |
| GSK | 4 | $69 |
| Exact Sciences | 3 | $63 |
| E.r. Squibb & Sons, L.L.C. | 3 | $62 |
| Abbott | 3 | $52 |
| Amarin Pharma, Inc. | 3 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| IBSA Pharma Inc. | 2 | $44 |
| Dexcom, Inc. | 2 | $42 |
| Smith+Nephew | 1 | $30 |
| Genentech USA, Inc. | 2 | $29 |
| Sanofi Pasteur Inc. | 1 | $29 |
| Merck | 2 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Alkermes, Inc. | 1 | $16 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
How this compares
$3,592 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 57 | $74,167 |
| MounjaroTirzepatide | 61 | $73,009 |
| EliquisApixaban | 56 | $58,994 |
| JardianceEmpagliflozin | 44 | $41,465 |
| OzempicSemaglutide | 41 | $39,255 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $27,828 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $27,431 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $24,547 |
| VraylarCariprazine Hcl | 13 | $17,161 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $15,946 |
| FarxigaDapagliflozin Propanediol | 14 | $13,548 |
| VascepaIcosapent Ethyl | 32 | $11,719 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $10,810 |
| Praluent PenAlirocumab | 19 | $9,457 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $631 | $147,176118 claims |
| PfizerEliquis | $143 | $58,99456 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $69 | $52,37593 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $203 | $47,30957 claims |
| Novo NordiskOzempic | $620 | $39,25541 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $331 | $22,77329 claims |
| AbbVieVraylar | $632 | $17,16113 claims |
| Cequr CorporationCequr Simplicity | $101 | $5,18512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.
Other family in Millersburg
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.